candesartan cilexetil has been researched along with Disease Exacerbation in 11 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Excerpt | Relevance | Reference |
|---|---|---|
| " After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12." | 2.74 | Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. ( Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009) |
| "Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system." | 2.47 | Differential clinical profile of candesartan compared to other angiotensin receptor blockers. ( Cernes, R; Mashavi, M; Zimlichman, R, 2011) |
| "In conclusion, progression of liver fibrosis reduces AGTR1 expression." | 1.34 | Expression of angiotensin II receptor type 1 is reduced in advanced rat liver fibrosis. ( Daudi, SM; Goeser, T; Kern, MA; Klanac, D; Kociok, N; Laue, O; Scheller, I; Schirmacher, P; Schulte, S; Steffen, HM; Töx, U, 2007) |
| "In vehicle-treated rats, proteinuria, glomerulosclerosis, interstitial mononuclear cell (MNC) infiltration and interstitial fibrosis developed." | 1.30 | Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. ( Fukuda, R; Imura, Y; Matsuo, T; Nagano, H; Nishikawa, K; Noda, M; Ohta, M; Shibouta, Y, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baguet, JP | 1 |
| Asmar, R | 1 |
| Valensi, P | 1 |
| Nisse-Durgeat, S | 1 |
| Mallion, JM | 1 |
| Cernes, R | 1 |
| Mashavi, M | 1 |
| Zimlichman, R | 1 |
| Kakizawa, H | 1 |
| Itoh, Y | 1 |
| Imamura, S | 1 |
| Matsumoto, T | 1 |
| Ishiwata, Y | 1 |
| Ono, Y | 1 |
| Yamamoto, K | 1 |
| Kato, T | 1 |
| Hayakawa, N | 1 |
| Oda, N | 1 |
| Goto, Y | 2 |
| Nagasaka, A | 1 |
| Senda, T | 1 |
| Itoh, M | 1 |
| Conen, D | 1 |
| Martina, B | 1 |
| Baumann, M | 1 |
| van den Born, BJ | 1 |
| Töx, U | 1 |
| Scheller, I | 1 |
| Kociok, N | 1 |
| Kern, MA | 1 |
| Klanac, D | 1 |
| Daudi, SM | 1 |
| Laue, O | 1 |
| Schirmacher, P | 1 |
| Goeser, T | 1 |
| Schulte, S | 1 |
| Steffen, HM | 1 |
| Noda, M | 2 |
| Fukuda, R | 1 |
| Matsuo, T | 2 |
| Ohta, M | 2 |
| Nagano, H | 1 |
| Imura, Y | 2 |
| Nishikawa, K | 1 |
| Shibouta, Y | 2 |
| Obata, J | 1 |
| Nakamura, T | 1 |
| Kuroyanagi, R | 1 |
| Yoshida, Y | 1 |
| Guo, DF | 1 |
| Inagami, T | 1 |
| Sugimoto, K | 1 |
| Tsuruoka, S | 1 |
| Matsushita, K | 1 |
| Fujimura, A | 1 |
| Nagano-Tsuge, H | 1 |
| Sekiguchi, M | 1 |
| Naka, T | 1 |
| Tsuyuki, RT | 1 |
| McKelvie, RS | 1 |
| Arnold, JM | 1 |
| Barretto, AC | 1 |
| Carvalho, AC | 1 |
| Isaac, DL | 1 |
| Kitching, AD | 1 |
| Piegas, LS | 1 |
| Teo, KK | 1 |
| Yusuf, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487] | Early Phase 1 | 42 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan cilexetil and Disease Exacerbation
| Article | Year |
|---|---|
Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Biphenyl Compounds; | 2011 |
2 trials available for candesartan cilexetil and Disease Exacerbation
| Article | Year |
|---|---|
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2009 |
Acute precipitants of congestive heart failure exacerbations.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Dise | 2001 |
8 other studies available for candesartan cilexetil and Disease Exacerbation
| Article | Year |
|---|---|
Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2004 |
Treating prehypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2006 |
Treating prehypertension.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2006 |
Expression of angiotensin II receptor type 1 is reduced in advanced rat liver fibrosis.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Collagen Type I; Disease Progression; Liver; Liver Cirr | 2007 |
Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1997 |
Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; | 1997 |
Effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 1999 |
Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2001 |